Enter subcutaneously or intramuscularly.
The dry substance is dissolved in the applied solvent immediately before use. In 1 ml of solvent dissolve the contents of not more than three vials of the preparation, which allows to reduce the injected volume of injection.
With anovulation (including polycystic ovary syndrome) in women in the case of previous treatment with clomiphene (with a saved menstrual cycle or with a violation of its periodicity).
Treatment begins in the first 7 days of the cycle. Stimulation is performed under the supervision of ultrasound (measure the size of the follicles) and / or the concentration of estrogens in the blood. The stimulation starts with a daily dose of 75-150 IU, increasing by 37.5 ME-75 ME, 2 times at intervals of 7 or (which is preferable) 14 days before the desired effect is achieved. The maximum dose of one injection should not exceed 225 IU. If there is no positive dynamics after 4 weeks, treatment is stopped. In the next cycle, stimulation should begin with a higher dose.
After the optimal size of the follicles is reached, after 24-48 hours after the last injection of FOLLITROPA®, 250 μg of recombinant human chorioradotropin (p-hCG) or 5000-10 000 IU hCG of human chorionic
gonadotropin (hCG).On the day of injection of hCG and the next day, the patient is recommended to have sexual intercourse.
In case of excessive ovarian response to stimulation, hCG administration should be abolished. In the next cycle, a lower dose of Pholllotrop® is prescribed compared to the previous dose.
When conducting controlled ovarian hyperstimulation for assisted reproductive technologies.
FOLLITROP® is prescribed daily for 150-225 ME, starting from 2 ^ 3 days of the cycle. The daily dose may vary, but usually does not exceed 450 IU. Treatment is continued until the follicles reach adequate size according to ultrasound (an average of 5-20 days).
24-48 hours after the last injection of FOLLITROP®, 250 μg of r-hCG or 5000-10 000 IU hCG are administered once to induce the final maturation of the follicles.
To suppress the endogenous release of LH and maintain it at a low level, analogues of gonadotropin-releasing hormone are used. For ovarian stimulation in women with severe deficiency of follicle-stimulating and luteinizing hormones.
The dose and scheme of treatment is selected by the doctor individually.
Typically, FOLLITROP® is administered daily subcutaneously in the techene for up to 5 weeks at the same time as luteinizing hormone.Treatment with FOLLITROP® is started at a dose of 75-150 IU simultaneously with lutropin alfa in a dose of 75 IU. If necessary, the dose of FOLLITROP® can be increased by 37.5 ME-75 ME, 2 times every 7-14 days.
In the absence of an adequate response to stimulation for 5 weeks, therapy should be discontinued and restarted in a new cycle at a higher dose.
After reaching the optimum size of the follicle of the follicles, 250 μg p-hCG or 5000-10 000 IU hCG are injected once 24-48 hours after the last injection of FOLLITROP® and lutropin alfa. On the day of injection of hCG and the next day, the patient is recommended to have sexual intercourse. As an alternative, intrauterine insemination can be performed.
In case of excessive ovarian response to stimulation, treatment should be discontinued and the administration of hCG should be canceled. In the next cycle, a lower dose of Pholllotrop® is prescribed compared to the previous dose.